

Ortho Regenerative Technologies' CSO, Michael Buschmann, PhD, Appointed Bioengineering Chair at George Mason University

Kirkland, QC, September 6, 2017 – Ortho Regenerative Technologies Inc. (“**Ortho RTi**” or the “**Company**”), an emerging Orthopaedic and Sports Medicine Technology company, wishes to congratulate its Chief Scientific Officer, Michael Buschmann, PhD, on his recent appointment as Bioengineering Chair, Professor and Eminent Scholar (an award from Virginia’s Center for Innovative Technology) at George Mason University (“Mason”) in Fairfax, VA.

Dr. Buschmann’s selection as the next chair of Bioengineering at Mason resulted from a highly competitive and rigorous recruitment process. Prior to his appointment, Dr. Buschmann established and led a multidisciplinary research program at Ecole Polytechnique in Montreal, QC, focusing on the use of biomaterials to repair cartilage, meniscus and bone and to deliver plasmid DNA and small interfering RNA.

Dr. Buschmann earned his PhD in 1992 in Medical Engineering and Medical Physics from the Massachusetts Institute of Technology in the Harvard-MIT Division of Health Sciences and Technology and conducted his postdoctoral studies at the ME Mueller Institute of Biomechanics, University of Bern, Switzerland. He became a faculty member at École Polytechnique in 1994, becoming a full professor in 2001. His research achievements include over 150 peer-reviewed articles, over 330 conference proceedings, 5 book chapters, over 75 invited presentations, 19 patent applications (7 granted), over 12,000 citations, and an h-index of 56. He has graduated 20 PhD students, 17 MSc students, and supervised 14 postdoctoral fellows. During his academic career at École Polytechnique, he obtained over \$50 million in external research funding as principal investigator.

Dr. Buschmann’s research work has been recognized by 19 prizes/awards and his abilities as an educator have earned him 6 teaching awards at École Polytechnique. Dr. Buschmann has received numerous awards for his research, including the prestigious Canada Research Chair Tier 1 in 2001 and in 2008, the Melville Medal of the American Society of Mechanical Engineering (“ASME”) in 1997, and Article of the Year for ASME Journal of Biomedical Engineering in 1996. In addition to Ortho RTi, Dr. Buschmann has been the driving force behind several biotech startup companies as founder or principal inventor.

“On behalf of the Board and staff at Ortho RTi, I would like to congratulate Michael on this prestigious appointment, said the Company’s Executive Chairman and CEO, Dr. Brent Norton. “It is very well deserved. Michael is a world-class researcher who has made fundamental and translational contributions to the fields of biomechanics, biomaterials, and nanomedicine. On a personal note, I look forward to continuing to work with him to bring products based on Ortho RTi’s proprietary biopolymer platform successfully to market.”

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries. We are committed to improving patients' lives through increasing the success rates of surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention. Visit us on the internet at www.orthorti.com.

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation's expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

For further Information, please contact:

Stephen Kilmer
Investor & Media Relations
647.872.4849
stephen@kilmerlucas.com